File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Translational research in breast cancer

TitleTranslational research in breast cancer
Authors
KeywordsBreast cancer
Hormone therapy
Neoadjuvant chemotherapy
Translational research
Trastuzumab
Issue Date2005
PublisherCambridge University Press. The Journal's web site is located at http://www.bco.org/
Citation
Breast Cancer Online, 2005, v. 12 n. 2, p. 86-90 How to Cite?
AbstractTranslational research (TR) involves both the development of novel diagnostics and novel therapeutics. These two major developmental areas are often associated with each other and these associations often bring new paradigms in the management of cancer patients. For example, the development of trastuzumab-based treatments has been conducted in harmony with the development of new methodologies to assess the expression of the Her-2 gene or protein, and from this, a therapeutic modality was established for breast cancer patients as a novel and individualized treatment system. TR covers a broad spectrum, from diagnosis to treatment, and it seems to act as a catalyst for developing novel paradigms. Therefore, it is crucial to conduct TR in clinical trials, in particular, prospective clinical trials. In this regard, TR can accelerate the development of new methodologies and increase trial efficiency. In this review, we describe the importance of TR, particularly that related to novel therapeutics.
Persistent Identifierhttp://hdl.handle.net/10722/45427
ISSN

 

DC FieldValueLanguage
dc.contributor.authorToi, Men_HK
dc.contributor.authorTakebayashi, Yen_HK
dc.contributor.authorChow, LWCen_HK
dc.date.accessioned2007-10-30T06:25:14Z-
dc.date.available2007-10-30T06:25:14Z-
dc.date.issued2005en_HK
dc.identifier.citationBreast Cancer Online, 2005, v. 12 n. 2, p. 86-90en_HK
dc.identifier.issn1470-9031en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45427-
dc.description.abstractTranslational research (TR) involves both the development of novel diagnostics and novel therapeutics. These two major developmental areas are often associated with each other and these associations often bring new paradigms in the management of cancer patients. For example, the development of trastuzumab-based treatments has been conducted in harmony with the development of new methodologies to assess the expression of the Her-2 gene or protein, and from this, a therapeutic modality was established for breast cancer patients as a novel and individualized treatment system. TR covers a broad spectrum, from diagnosis to treatment, and it seems to act as a catalyst for developing novel paradigms. Therefore, it is crucial to conduct TR in clinical trials, in particular, prospective clinical trials. In this regard, TR can accelerate the development of new methodologies and increase trial efficiency. In this review, we describe the importance of TR, particularly that related to novel therapeutics.en_HK
dc.format.extent80763 bytes-
dc.format.extent2072 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherCambridge University Press. The Journal's web site is located at http://www.bco.org/en_HK
dc.rightsBreast Cancer Online. Copyright © Cambridge University Press.en_HK
dc.subjectBreast cancer-
dc.subjectHormone therapy-
dc.subjectNeoadjuvant chemotherapy-
dc.subjectTranslational research-
dc.subjectTrastuzumab-
dc.subject.meshBreast Neoplasms - diagnosis - genetics - therapyen_HK
dc.subject.meshMedical Oncology - trendsen_HK
dc.subject.meshResearch Designen_HK
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshNeoadjuvant Therapyen_HK
dc.titleTranslational research in breast canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1470-9031&volume=12&issue=2&spage=86&epage=90&date=2005&atitle=Translational+research+in+breast+canceren_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.2325/jbcs.12.86en_HK
dc.identifier.pmid15858437en_HK
dc.identifier.scopuseid_2-s2.0-24344447301-
dc.identifier.hkuros97893-
dc.identifier.citeulike4313979-
dc.identifier.issnl1470-9031-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats